Related references
Note: Only part of the references are listed.Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape
Xuemei Xie et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2022)
Smart Lipid-Polysaccharide Nanoparticles for Targeted Delivery of Doxorubicin to Breast Cancer Cells
Manuela Curcio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets
Alberto Zambelli et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2022)
Enhanced DNA damage response through RAD50 in triple negative breast cancer resistant and cancer stem-like cells contributes to chemoresistance
Etna Abad et al.
FEBS JOURNAL (2021)
Synergistic co-loading of vincristine improved chemotherapeutic potential of pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer
Saikat Ghosh et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2021)
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
Yuan Yuan et al.
ONCOLOGIST (2021)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy
Robyn Broad et al.
BRITISH JOURNAL OF CANCER (2021)
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Xupeng Bai et al.
CANCER LETTERS (2021)
Novel immune targets for the treatment of triple-negative breast cancer
Chiara Corti et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Signaling pathways essential for triple-negative breast cancer stem-like cells
Sidse Ehnnsen et al.
STEM CELLS (2021)
Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer
Milica Nedeljkovic et al.
BREAST CANCER (2021)
Stimuli-Responsive, Plasmonic Nanogel for Dual Delivery of Curcumin and Photothermal Therapy for Cancer Treatment
Fadak Howaili et al.
FRONTIERS IN CHEMISTRY (2021)
MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance
Dawid Mehlich et al.
CELL DEATH & DISEASE (2021)
The Oxygen-Generating Calcium Peroxide-Modified Magnetic Nanoparticles Attenuate Hypoxia-Induced Chemoresistance in Triple-Negative Breast Cancer
Fong-Yu Cheng et al.
CANCERS (2021)
Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer
Bo Gao et al.
FRONTIERS IN ONCOLOGY (2021)
Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells
Veronica Vella et al.
CELLS (2021)
Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
Meng Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Polyglutamic acid-based crosslinked doxorubicin nanogels as an anti-metastatic treatment for triple negative breast cancer
Aroa Duro-Castano et al.
JOURNAL OF CONTROLLED RELEASE (2021)
BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated β-catenin acetylation
Siqi Li et al.
JOURNAL OF PATHOLOGY (2021)
ICG-Loaded PEG-Modified Black Phosphorus Nanosheets for Fluorescence Imaging-Guided Breast Cancer Therapy
Wanwan Pan et al.
ACS OMEGA (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A smart viral vector for targeted delivery of hydrophobic drugs
Sukanya Ghosh et al.
SCIENTIFIC REPORTS (2021)
The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies
Vivek Kumar et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Yanghong Ni et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway
Huayu Hu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
Lori J. Goldstein et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Arielle L. Heeke et al.
CANCER AND METASTASIS REVIEWS (2021)
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
Kurt W. Evans et al.
CANCER RESEARCH (2021)
Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles
Rujing Chen et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)
Dual Functions of Riboflavin-functionalized Poly(lactic-co-glycolic acid) Nanoparticles for Enhanced Drug Delivery Efficiency and Photodynamic Therapy in Triple-negative Breast Cancer Cells
Wid Mekseriwattana et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2021)
Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer
Peiqi Zhao et al.
JOURNAL OF NANOBIOTECHNOLOGY (2021)
Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
Pere Llinas-Arias et al.
CANCERS (2021)
Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis
Patricia Fernandez-Nogueira et al.
CANCERS (2021)
Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p
Bayan Al-Momany et al.
CURRENT MOLECULAR PHARMACOLOGY (2021)
Identification of TAZ-Dependent Breast Cancer Vulnerabilities Using a Chemical Genomics Screening Approach
He Shen et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer
Jia-hui Ye et al.
JOURNAL OF CANCER (2021)
Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes
Alfredo Nunez-Rivera et al.
BEILSTEIN JOURNAL OF NANOTECHNOLOGY (2020)
HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling
Jie Bai et al.
WORLD JOURNAL OF STEM CELLS (2020)
Prolonged Local In Vivo Delivery of Stimuli-Responsive Nanogels That Rapidly Release Doxorubicin in Triple-Negative Breast Cancer Cells
Yi Zhang et al.
ADVANCED HEALTHCARE MATERIALS (2020)
EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress
Ruishan Zhang et al.
CANCER CELL INTERNATIONAL (2020)
Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets
Rosamaria Lappano et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer
Crystal C. Lipsey et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
Laura Breen et al.
INVESTIGATIONAL NEW DRUGS (2020)
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Ozge Saatci et al.
NATURE COMMUNICATIONS (2020)
IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells
Damiano Cosimo Rigiracciolo et al.
CELLS (2020)
Metabolic Reprogramming in Triple-Negative Breast Cancer
Sun Xiangyu et al.
FRONTIERS IN ONCOLOGY (2020)
Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells
Andrew Sulaiman et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Insights into the Role of Estrogen Receptor beta in Triple-Negative Breast Cancer
Assunta Sellitto et al.
CANCERS (2020)
The IL1 beta-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs)
Rosamaria Lappano et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition
Jialong Fan et al.
ACTA BIOMATERIALIA (2020)
Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple -Negative Breast Cancer Cell Lines
Saeko Teraoka et al.
JOURNAL OF SURGICAL RESEARCH (2020)
Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE
Jianghua Qiao et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer
Piotr Przanowski et al.
CANCER RESEARCH (2020)
Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer
Christopher M. Bailey et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2020)
Chitosan Hydrogels for Synergistic Delivery of Chemotherapeutics to Triple Negative Breast Cancer Cells and Spheroids
John D. Schneible et al.
PHARMACEUTICAL RESEARCH (2020)
Roles of ABCC1 and ABCC4 in Proliferation and Migration of Breast Cancer Cell Lines
Floren G. Low et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Vikas Jain et al.
JOURNAL OF CONTROLLED RELEASE (2020)
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Qin Wu et al.
NATURE COMMUNICATIONS (2020)
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
Gagan K. Gupta et al.
CANCERS (2020)
Molecular mechanisms of breast cancer chemoresistance by immune checkpoints
Narges Dastmalchi et al.
LIFE SCIENCES (2020)
Cisplatin Prodrug-Loaded Nanoparticles Based on Physalis Mottle Virus for Cancer Therapy
He Hu et al.
MOLECULAR PHARMACEUTICS (2020)
Estrogen Actions in Triple-Negative Breast Cancer
Oliver Treeck et al.
CELLS (2020)
Exploiting DNA repair defects in triple negative breast cancer to improve cell killing
Kevin J. Lee et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
A self-assembled RNA-triple helix hydrogel drug delivery system targeting triple-negative breast cancer
Lairong Ding et al.
JOURNAL OF MATERIALS CHEMISTRY B (2020)
Glycopolymer decorated multiwalled carbon nanotubes for dual targeted breast cancer therapy
Pinar Sinem Omurtag Ozgen et al.
JOURNAL OF MATERIALS CHEMISTRY B (2020)
Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels
Anna De Blasio et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells
Damiano Cosimo Rigiracciolo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy
Jiabei He et al.
CELL DEATH & DISEASE (2019)
The role of photodynamic therapy on multidrug resistant breast cancer
Eric Chekwube Aniogo et al.
CANCER CELL INTERNATIONAL (2019)
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
Utpal K. Mukhopadhyay et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers
Mathilde Vinet et al.
CANCER MEDICINE (2019)
Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer
Hao Xie et al.
CELLS (2019)
Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer
Na Yang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer
Yulia Liubomirski et al.
FRONTIERS IN IMMUNOLOGY (2019)
Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer
Yulia Liubomirski et al.
FRONTIERS IN IMMUNOLOGY (2019)
Prognostic role of GPER/Ezrin in triple-negative breast cancer is associated with menopausal status
Shuang Ye et al.
ENDOCRINE CONNECTIONS (2019)
The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
Priyanka Bhateja et al.
CANCERS (2019)
Cancer cell membrane-coated mesoporous silica loaded with superparamagnetic ferroferric oxide and Paclitaxel for the combination of Chemo/Magnetocaloric therapy on MDA-MB-231 cells
Defu Cai et al.
SCIENTIFIC REPORTS (2019)
Anti-tumor activity of BET inhibitors in androgen-receptor- expressing triple-negative breast cancer
In Hae Park et al.
SCIENTIFIC REPORTS (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer sternness and metastasis
Yunfei Li et al.
BIOMATERIALS (2019)
Impact of Topoisomerase II, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy
Fouzia Guestini et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer
Yangyang Cui et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells
Anna A. Marusiak et al.
ONCOGENE (2019)
Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells
Maxine Bauzon et al.
ONCOIMMUNOLOGY (2019)
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
Jung Ok Lee et al.
BREAST CANCER RESEARCH (2019)
Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2
Arunkumar Arumugam et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
GSK3 regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer
Geraldine Vidhya Vijay et al.
BREAST CANCER RESEARCH (2019)
Three-dimensional tumor model mimics stromal - breast cancer cells signaling
Stephanie Lemmo Ham et al.
ONCOTARGET (2018)
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers
N. J. Birkbak et al.
ANNALS OF ONCOLOGY (2018)
TGF-beta plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating sternness, EMT and apoptosis
Xiaodan Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism
Marco Fiorillo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2018)
Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents
Matteo Santoni et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
S Modi et al.
CANCER RESEARCH (2018)
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
Haiquan Lu et al.
CANCER RESEARCH (2018)
KiSS1 gene as a novel mediator of TGF beta-mediated cell invasion in triple negative breast cancer
Jun Tian et al.
CELLULAR SIGNALLING (2018)
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
Michael Carducci et al.
INVESTIGATIONAL NEW DRUGS (2018)
Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1α
Ke Wang et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2018)
STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling
Lufeng Zheng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states
Andrew Sulaiman et al.
MOLECULAR ONCOLOGY (2018)
Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide
Lu Lu et al.
ONCOGENE (2018)
Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM
Xiang Zhang et al.
CELL DEATH & DISEASE (2018)
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer
Aurelie S. Cazet et al.
NATURE COMMUNICATIONS (2018)
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
Touko Inao et al.
Oncotarget (2018)
Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer
Jeff C. Liu et al.
CELL REPORTS (2018)
HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway
Yi Liu et al.
STEM CELL REPORTS (2018)
Notch Signaling as a Regulator of the Tumor Immune Response: To Target or Not To Target?
Mahnaz Janghorban et al.
FRONTIERS IN IMMUNOLOGY (2018)
Novel folic acid-conjugated doxorubicin loaded β-lactoglobulin nanoparticles induce apoptosis in breast cancer cells
Zahra Kayani et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Cellular uptake and apoptotic potential of rhenium labeled magnetic protein cages in MDA-MB-231 cells
Elif Asik et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2018)
ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis
Jordan M. Reese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
Jun Tian et al.
BRITISH JOURNAL OF CANCER (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance
Gaofeng Xiong et al.
NATURE COMMUNICATIONS (2018)
Notch Signaling Regulates Mitochondrial Metabolism and NF-kappa B Activity in Triple-Negative Breast Cancer Cells via IKK alpha-Dependent Non-canonical Pathways
Fokhrul Hossain et al.
FRONTIERS IN ONCOLOGY (2018)
Modulation of Hypoxia-Induced Chemoresistance to Polymeric Micellar Cisplatin: The Effect of Ligand Modification of Micellar Carrier Versus Inhibition of the Mediators of Drug Resistance
Hoda Soleymani Abyaneh et al.
PHARMACEUTICS (2018)
Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis
Kideok Jin et al.
BREAST CANCER RESEARCH (2018)
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2018)
Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Anthony Cheung et al.
CLINICAL CANCER RESEARCH (2018)
Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer
M. M-Rabet et al.
ANNALS OF ONCOLOGY (2017)
Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1
H. Liu et al.
ONCOGENE (2017)
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer
L. L. da Motta et al.
ONCOGENE (2017)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer
Tyler J. Kochel et al.
ONCOTARGET (2017)
The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231)
Peyman Eivazy et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2017)
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
Sherif Abdelaziz Ibrahim et al.
MOLECULAR CANCER (2017)
Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform
Jingga Morry et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Potato virus X, a filamentous plant viral nanoparticle for doxorubicin delivery in cancer therapy
Duc H. T. Le et al.
NANOSCALE (2017)
Cytotoxic effect of albumin coated copper nanoparticle on human breast cancer cells of MDA-MB 231
Marzieh Azizi et al.
PLOS ONE (2017)
Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells
Yoshikazu Koike et al.
BREAST CANCER (2017)
STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer
Wei-Ying Kuo et al.
THERANOSTICS (2017)
Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer
Bing Feng et al.
BIOMATERIALS SCIENCE (2017)
STAT3 but Not HIF-1 Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line
Hoda Soleymani Abyaneh et al.
CANCERS (2017)
G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance
Alexandra Blake et al.
SCIENTIFIC REPORTS (2017)
H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
S. Mazzucchelli et al.
SCIENTIFIC REPORTS (2017)
Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer
Melissa Quintero et al.
BMC CANCER (2017)
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
Katharina Gohr et al.
BMC CANCER (2017)
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
Kyung-Min Lee et al.
CELL METABOLISM (2017)
Folate/N-acetyl glucosamine conjugated mesoporous silica nanoparticles for targeting breast cancer cells: A comparative study
Pramod Kumar et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2017)
Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
Thomas M. Cardillo et al.
CLINICAL CANCER RESEARCH (2017)
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
Atsuko Kitano et al.
ESMO OPEN (2017)
Breast cancer subtype distribution is different in normal weight, overweight, and obese women
Victoria Gershuni et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis
Shadia Al-Bahlani et al.
APOPTOSIS (2017)
E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer
Liqiu Liao et al.
CANCER RESEARCH (2017)
Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification
Fouzia Guestini et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Transforming growth factor-beta increases breast cancer stem cell population partially through upregulating PMEPA1 expression
Zhi Nie et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2016)
High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer
Xiaojia Huang et al.
BREAST (2016)
Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses
Anthony Cao et al.
CANCER RESEARCH (2016)
PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis
Debangshu Samanta et al.
CANCER RESEARCH (2016)
BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane
T. Ishikawa et al.
EJSO (2016)
Paclitaxel-Loaded TPGS-b-PCL Nanoparticles: In Vitro Cytotoxicity and Cellular Uptake in MCF-7 and MDA-MB-231 Cells versus mPEG-b-PCL Nanoparticles and Abraxane (R)
Ezequiel Bernabeu et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2016)
Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer
Mengmeng Niu et al.
MOLECULAR PHARMACEUTICS (2016)
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression
Dai Horiuchi et al.
NATURE MEDICINE (2016)
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
Fara Braso-Maristany et al.
NATURE MEDICINE (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer
Min-Sun Jin et al.
VIRCHOWS ARCHIV (2016)
MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors
Masayuki Hiraki et al.
SCIENTIFIC REPORTS (2016)
ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer
Peng Guo et al.
THERANOSTICS (2016)
Triple-Layered pH-Responsive Micelleplexes Loaded with siRNA and Cisplatin Prodrug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer
Haijun Yu et al.
THERANOSTICS (2016)
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Yi-Rong Liu et al.
BREAST CANCER RESEARCH (2016)
β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer
Hsin-Ling Yin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy
Rammohan Devulapally et al.
ACS NANO (2015)
Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxel
Shan Tang et al.
BIOMATERIALS (2015)
Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
Aleix Prat et al.
BMC MEDICINE (2015)
Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer
Chee Leong Cheng et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
A. Reeder et al.
BRITISH JOURNAL OF CANCER (2015)
Down-regulating HIF-1 by lentivirus-mediated shRNA for therapy of triple negative breast cancer
Shuang Li et al.
CANCER BIOLOGY & THERAPY (2015)
Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing Chemotherapies
Young Joo Jeon et al.
CANCER CELL (2015)
Identifying and targeting tumor-initiating cells in the treatment of breast cancer
Wei Wei et al.
ENDOCRINE-RELATED CANCER (2015)
AMPK inhibits MTDH expression via GSK3 and SIRT1 activation: potential role in triple negative breast cancer cell proliferation
Paradesi Naidu Gollavilli et al.
FEBS JOURNAL (2015)
Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway
Cuixia Yang et al.
MEDICAL ONCOLOGY (2015)
A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness
Tackhoon Kim et al.
NATURE COMMUNICATIONS (2015)
BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
Robin Dufour et al.
SCIENTIFIC REPORTS (2015)
RNA-Based TWIST1 Inhibition via Dendrimer Complex to Reduce Breast Cancer Cell Metastasis
James Finlay et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Triple-negative breast cancer: investigating potential molecular therapeutic target
Anselmo Papa et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling
Marie-Kristin von Wahlde et al.
GYNECOLOGICAL ENDOCRINOLOGY (2015)
TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells
M. Bartucci et al.
ONCOGENE (2015)
Hydrogel Doped with Nanoparticles for Local Sustained Release of siRNA in Breast Cancer
Nathaly Segovia et al.
ADVANCED HEALTHCARE MATERIALS (2015)
Drug Delivery with PEGylated MoS2 Nano-sheets for Combined Photothermal and Chemotherapy of Cancer
Teng Liu et al.
ADVANCED MATERIALS (2014)
Enriched CD44+/CD24- population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC)
Fei Ma et al.
CANCER LETTERS (2014)
Peptide conjugated polymeric nanoparticles as a carrier for targeted delivery of docetaxel
Hitesh Kulhari et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2014)
Factors associated with breast cancer mortality after local recurrence
R. Dent et al.
CURRENT ONCOLOGY (2014)
Unique Features of Young Age Breast Cancer and Its Management
Han-Byoel Lee et al.
JOURNAL OF BREAST CANCER (2014)
GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells
Tenghua Yu et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
MTBP Is Overexpressed in Triple-Negative Breast Cancer and Contributes to Its Growth and Survival
Brian C. Grieb et al.
MOLECULAR CANCER RESEARCH (2014)
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
Xi Chen et al.
NATURE (2014)
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Marta Bonotto et al.
ONCOLOGIST (2014)
Design and In Vitro Evaluation of Layer by Layer siRNA Nanovectors Targeting Breast Tumor Initiating Cells
Hamsa Jaganathan et al.
PLOS ONE (2014)
被撤回的出版物: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells (Retracted article. See vol. 119, 2022)
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Chloroquine Eliminates Cancer Stem Cells Through Deregulation of Jak2 and DNMT1
Dong Soon Choi et al.
STEM CELLS (2014)
Cyclodextrin and Polyethylenimine Functionalized Mesoporous Silica Nanoparticles for Delivery of siRNA Cancer Therapeutics
Jianliang Shen et al.
THERANOSTICS (2014)
KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer
Stina M. Singel et al.
NEOPLASIA (2014)
GPER function in breast cancer: an overview
Rosamaria Lappano et al.
FRONTIERS IN ENDOCRINOLOGY (2014)
Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment
Zhou J. Deng et al.
ACS NANO (2013)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth
Zhaohui Wang et al.
BIOMATERIALS (2013)
High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival
Akimitsu Yamada et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Maxwell N. Skor et al.
CLINICAL CANCER RESEARCH (2013)
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Anne F. Schott et al.
CLINICAL CANCER RESEARCH (2013)
IMP3 Protein Promotes Chemoresistance in Breast Cancer Cells by Regulating Breast Cancer Resistance Protein (ABCG2) Expression
Sanjoy Samanta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Neil E. Bhola et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes
Enilze Ribeiro et al.
PLOS ONE (2013)
Reactivation of Estrogen Receptor a by Vorinostat Sensitizes Mesenchymal-Like Triple-Negative Breast Cancer to Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor
Karri Stark et al.
PLOS ONE (2013)
Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation
A. Notte et al.
CELL DEATH & DISEASE (2013)
Cytotoxicity of Biologically Synthesized Silver Nanoparticles in MDA-MB-231 Human Breast Cancer Cells
Sangiliyandi Gurunathan et al.
BIOMED RESEARCH INTERNATIONAL (2013)
A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer
Fatemeh Karami et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery
Adem Guven et al.
BIOMATERIALS (2012)
Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy
Rainer Girgert et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
PEGylated Liposomal Doxorubicin Targeted to α5β1-Expressing MDA-MB-231 Breast Cancer Cells
Kamlesh Shroff et al.
LANGMUIR (2012)
Functional Aspects of PARP1 in DNA Repair and Transcription
Hui Ling Ko et al.
BIOMOLECULES (2012)
Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma
Hermien Hartog et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73
Su Wei Wong et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Tanaya Shree et al.
GENES & DEVELOPMENT (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Hypoxia and Senescence: The Impact of Oxygenation on Tumor Suppression
Scott M. Welford et al.
MOLECULAR CANCER RESEARCH (2011)
CANCER Macrophages limit chemotherapy
Michele De Palma et al.
NATURE (2011)
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
Christophe Ginestier et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia
Lionel Flamant et al.
MOLECULAR CANCER (2010)
Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
Rafael Cubas et al.
MOLECULAR CANCER (2010)
Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol
Ming Zhou et al.
MOLECULAR CANCER (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
ABC transporters in cancer: more than just drug efflux pumps
Jamie I. Fletcher et al.
NATURE REVIEWS CANCER (2010)
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy
E. Y. Tan et al.
BRITISH JOURNAL OF CANCER (2009)
In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles
Jing-Liang Li et al.
CANCER LETTERS (2009)
Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
Emmanuelle Charafe-Jauffret et al.
CANCER RESEARCH (2009)
A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer
Theresa A. DiMeo et al.
CANCER RESEARCH (2009)
Mannose-targeted mesoporous silica nanoparticles for photodynamic therapy
David Brevet et al.
CHEMICAL COMMUNICATIONS (2009)
Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1
Richard Sullivan et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Hypoxia-driven selection of the metastatic phenotype
Richard Sullivan et al.
CANCER AND METASTASIS REVIEWS (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
MRP8/ABCC11 directly confers resistance to 5-fluorouracil
Tetsuya Oguri et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
Bruce G. Haffty et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer
Yong Wang et al.
NATURE MATERIALS (2006)
Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells
T Gritsko et al.
CLINICAL CANCER RESEARCH (2006)
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis
Gerald Batist et al.
ANTI-CANCER DRUGS (2006)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The role of the BRCA1 tumor suppressor in DNA double-strand break repair
JR Zhang et al.
MOLECULAR CANCER RESEARCH (2005)
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
I Beuvink et al.
CELL (2005)
Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide
AP Simoes-Wüst et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair
AR Hartman et al.
NATURE GENETICS (2002)
Share Paper
